ADAR1 Capital Management, LLC purchased $88K of NXTC (indirect holdings)
ADAR1 Capital Management, LLC purchased 17,608 indirectly-held shares of NextCure, Inc. (NXTC) at an average of $4.98 ($4.95–$5.00) across 4 trades over 2026-07-27 to 2026-07-29.
How this was made
The 30-second read
Why it matters
The disclosed fact is the purchase activity by a significant holder (10% owner) at roughly $4.95 to $5.00 per share across four trades, with holdings after the transaction at 393,266 shares.
Market read
Traders may view the transaction as modestly supportive sentiment, but it does not introduce new fundamentals or a time-critical corporate event.
What to watch
The filing is for indirect holdings and does not state intent, liquidity constraints, or whether the purchases were opportunistic versus planned outside a 10b5-1 framework.
Background
The article is a primary-source SEC Form 4 insider transaction disclosure for NextCure, Inc.
Ticker impact
NextCure Form 4 shows ADAR1 Capital Management, a 10% owner, bought 17,608 shares in open-market trades at about $4.98.
Likely limited near-term impact; any effect is more sentiment/positioning than fundamentals.
Form 4 provides transaction details (size, price range, dates) but no accompanying guidance, deal, or regulatory event. The indirect nature and lack of 10b5-1 plan context reduce interpretability for timing.
Market effects
No sector-level read-through is provided beyond a single-company ownership transaction.
None indicated.
None indicated.
Counterpoint
A 10% owner open-market purchase can be routine portfolio rebalancing and may not signal near-term upside without follow-on disclosures.
Key entities
- issuerNextCure, Inc.
NXTC, subject of the Form 4 insider transaction disclosure.
- 10% ownerADAR1 Capital Management, LLC
Reporter of the indirect open-market purchase of NXTC shares.
